News

Polykon Manufacturing LLC merges with Seppic Inc. and becomes Seppic Inc. Richmond

Since its opening in 2020 in Richmond, Virginia, the Polykon Manufacturing LLC facility has strengthened Seppic’s proximity to our North American customers and expanded our manufacturing capabilities. Effective January 1, 2024, Polykon Manufacturing LLC took the next step by merging with its parent company, Seppic Inc.

This change brings consistency to the organization of Seppic’s manufacturing facilities and supports the company’s strategy to deliver a simplified customer experience. Seppic continues to grow by addressing multiple markets around the world, always with the highest level of service, while strengthening its brand image in the United States.

Seppic Inc. Richmond produces in particular SEPIMAX ZEN™, SEPINOV™ EMT 10, SEPINOV™ WEO, SIMULGEL™ NS, or SIMULGEL INS 100™. As a major global player in rheology modifiers, the Seppic Group continually invests in its production facilities in the United States to provide a high level of service to its customers.

Recent News

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75